- Home
- COEP vs SLGL Comparison
COEP vs SLGL Comparison
Compare COEP & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | SLGL |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | COEP | SLGL |
|---|---|---|
| Price | $15.15 | $42.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 91.6K | 15.3K |
| Earning Date | 11-14-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $500,996.00 | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $2.31 | $4.02 |
| 52 Week High | $21.41 | $52.26 |
Technical Indicators
Market Signals| Indicator | COEP | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 57.44 |
| Support Level | $14.82 | $38.30 |
| Resistance Level | $16.60 | $44.43 |
| Average True Range (ATR) | 1.43 | 3.59 |
| MACD | -0.24 | 0.02 |
| Stochastic Oscillator | 1.18 | 68.45 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.